Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial

Abstract Background Cardiogenic shock (CS) is associated with significant morbidity and mortality. The impact of beta-blocker (BB) use on patients who develop CS remains unknown. We sought to evaluate the clinical outcomes and hemodynamic response profiles in patients treated with BB in the 24 h pri...

Description complète

Détails bibliographiques

Auteurs principaux:	Pietro Di Santo, Rebecca Mathew, Richard G. Jung, Trevor Simard, Stephanie Skanes, Brennan Mao, F. Daniel Ramirez, Jeffrey A. Marbach, Omar Abdel-Razek, Pouya Motazedian, Simon Parlow, Kevin E. Boczar, Gianni D’Egidio, Steven Hawken, Jordan Bernick, George A. Wells, Alexander Dick, Derek Y. So, Christopher Glover, Juan J. Russo, Caroline McGuinty, Benjamin Hibbert, the CAPITAL DOREMI investigators
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2021-08-01
Collection:	Critical Care
Sujets:	Cardiogenic shock Beta-blocker Inotropes Milrinone Dobutamine
Accès en ligne:	https://doi.org/10.1186/s13054-021-03706-2
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!